Table of Contents
EXECUTIVE SUMMARY
INTRODUCTION
2.1 Global Healthcare Expenditure to Reach $9.17 Trillion by 2020
2.2 US Healthcare Expenditure Consistently Higher Than Other Major Markets
2.3 Factors Contributing to Constrained Healthcare Budgets
2.4 GBI Research Industry Survey: Most Important Factors Constraining Healthcare Budgets I
2.5 GBI Research Industry Survey: Therapy Areas Contributing to Constrained Healthcare Budgets I
2.6 How Do Constraining Healthcare Budgets Impact the Pharmaceutical Industry?
LANDSCAPE
3.1 Pharma in a Changing Environment I
3.2 Current Landscape in Key Mature Markets I
3.3 Current Landscape in Key Emerging Markets I
3.4 GBI Research Industry Survey: Pharmaceutical Pricing and Reimbursement Policies in Europe
3.5 GBI Research Industry Survey: Pharmaceutical Pricing and Reimbursement Policies in the US
3.6 GBI Research Industry Survey: Pharmaceutical Pricing and Reimbursement Policies in the Asia-Pacific
MAIN POLICIES APPLIED IN KEY MARKETS
4.1 Main Pricing and Reimbursement Policies Applied in Key Markets II
4.2 Health Technology Assessment Overview
4.3 Heterogeneity in Health Technology Assessment ‘Value’
4.4 GBI Research Industry Survey: Future Health Technology Assessment Evaluation Criteria in Europe
4.5 GBI Research Industry Survey: Future Health Technology Assessment Evaluation Criteria in US
4.6 GBI Research Industry Survey: Future Health Technology Assessment Evaluation Criteria in Asia-Pacific
4.7 Overview of Managed Entry Agreements (MEA)
4.8 GBI Research Industry Survey: Future of Managed Entry Agreements in Europe
4.9 GBI Research Industry Survey: Future of Managed Entry Agreements in the US
4.10 GBI Research Industry Survey: Future of Managed Entry Agreements in Asia-Pacific
4.11 Pros and Cons of Managed Entry Agreements
IMPACT ON PHARMACEUTICAL INDUSTRY
5.1 GBI Research Industry Survey: Impact of Constrained Healthcare Budgets on the Pharmaceutical Industry
5.2 Negative impacts of Constrained Healthcare Budgets
5.3 Impact on R&D
5.4 Future R&D priorities
5.5 Perspective of the Industry on Future R&D Priorities
5.6 Positive Impacts of Constrained Healthcare Budgets
5.7 Impact of FDA reforms
RESPONSE OF PHARMA COMPANIES
6.1 GBI Research Industry Survey: Industry Response
6.2 Strategic Manoeuvres: Mergers and Acquisitions
6.3 Implementation of digital technology
6.4 R&D changes
6.5 Operational changes: Outsourcing
6.6 Payer engagement
6.7 Integrated Care – the Sixth Emerging Business Strategy?
CONCLUSION
BIBLIOGRAPHY